CG
ERNA icon

Cutler Group’s Eterna Therapeutics ERNA Stock Holding History

Cutler Group’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$9K – 5537
2021
Q3 		$9K Buy
3
+2
+200% +$173K ﹤0.01% 3996
2021
Q2 		$2K Buy
+1
New +$144K ﹤0.01% 4977

Other funds holding ERNA

CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cutler Group's ERNA Position: Q2 2022 in Review

Cutler Group held its Eterna Therapeutics (ERNA) position steady in Q2 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5143.

Cutler Group first reported a position in ERNA in Q2 2021 and has held it in 1 quarter since. The position peaked at $75K in Q2 2021. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

  • Cutler Group held 0 shares of Eterna Therapeutics worth $0 as of Q2 2022.
  • Cutler Group left its Eterna Therapeutics share count unchanged in Q2 2022.
  • Eterna Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q2 2022, its #5143 holding.
  • Cutler Group first reported a position in Eterna Therapeutics in Q2 2021 and has held it in 1 quarter since.
  • Cutler Group's Eterna Therapeutics position peaked at $75K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.